Treatment options for refractory chronic lymphocytic leukemia

Marina Motta; Alessandra Ferrajoli

doi:10.2217/EBO.11.343

Treatment options for refractory chronic lymphocytic leukemia

Marina Motta, Alessandra Ferrajoli

Leukemia

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Patients with purine analog-refractory chronic lymphocytic leukemia (CLL) have short survival and limited treatment options. In recent years the number of available treatment modalities for refractory CLL patients has increased. The monoclonal antibodies alemtuzumab and ofatumumab showed activity in patients with fludarabine-refractory CLL. Chemoimmunotherapy regimen showed activity in patients with refractory CLL. Agents with different mechanism of action as lenalidomide and flavopiridol showed activity in patients with refractory CLL. Allogeneic stem cell transplantation is a reasonable treatment option for young patients with poor-risk CLL (ultra high risk, del 17p).

Original language	English (US)
Title of host publication	Advances in the Treatment of B-Cell Chronic Lymphocytic Leukemia
Publisher	Future Medicine Ltd.
Pages	67-74
Number of pages	8
ISBN (Electronic)	9781780840444
ISBN (Print)	9781780841229
DOIs	https://doi.org/10.2217/EBO.11.343
State	Published - Mar 1 2012

ASJC Scopus subject areas

General Medicine

Access to Document

10.2217/EBO.11.343

Cite this

@inbook{66480b099a1a43acaa8134f5a79c87a8,

title = "Treatment options for refractory chronic lymphocytic leukemia",

abstract = "Patients with purine analog-refractory chronic lymphocytic leukemia (CLL) have short survival and limited treatment options. In recent years the number of available treatment modalities for refractory CLL patients has increased. The monoclonal antibodies alemtuzumab and ofatumumab showed activity in patients with fludarabine-refractory CLL. Chemoimmunotherapy regimen showed activity in patients with refractory CLL. Agents with different mechanism of action as lenalidomide and flavopiridol showed activity in patients with refractory CLL. Allogeneic stem cell transplantation is a reasonable treatment option for young patients with poor-risk CLL (ultra high risk, del 17p).",

author = "Marina Motta and Alessandra Ferrajoli",

year = "2012",

month = mar,

day = "1",

doi = "10.2217/EBO.11.343",

language = "English (US)",

isbn = "9781780841229",

pages = "67--74",

booktitle = "Advances in the Treatment of B-Cell Chronic Lymphocytic Leukemia",

publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - Treatment options for refractory chronic lymphocytic leukemia

AU - Motta, Marina

AU - Ferrajoli, Alessandra

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Patients with purine analog-refractory chronic lymphocytic leukemia (CLL) have short survival and limited treatment options. In recent years the number of available treatment modalities for refractory CLL patients has increased. The monoclonal antibodies alemtuzumab and ofatumumab showed activity in patients with fludarabine-refractory CLL. Chemoimmunotherapy regimen showed activity in patients with refractory CLL. Agents with different mechanism of action as lenalidomide and flavopiridol showed activity in patients with refractory CLL. Allogeneic stem cell transplantation is a reasonable treatment option for young patients with poor-risk CLL (ultra high risk, del 17p).

AB - Patients with purine analog-refractory chronic lymphocytic leukemia (CLL) have short survival and limited treatment options. In recent years the number of available treatment modalities for refractory CLL patients has increased. The monoclonal antibodies alemtuzumab and ofatumumab showed activity in patients with fludarabine-refractory CLL. Chemoimmunotherapy regimen showed activity in patients with refractory CLL. Agents with different mechanism of action as lenalidomide and flavopiridol showed activity in patients with refractory CLL. Allogeneic stem cell transplantation is a reasonable treatment option for young patients with poor-risk CLL (ultra high risk, del 17p).

UR - http://www.scopus.com/inward/record.url?scp=84957647260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957647260&partnerID=8YFLogxK

U2 - 10.2217/EBO.11.343

DO - 10.2217/EBO.11.343

M3 - Chapter

AN - SCOPUS:84957647260

SN - 9781780841229

SP - 67

EP - 74

BT - Advances in the Treatment of B-Cell Chronic Lymphocytic Leukemia

PB - Future Medicine Ltd.

ER -

Treatment options for refractory chronic lymphocytic leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this